new glp-1 receptor agonists Guidelines for Type 2 Diabetes in 2025 GLP-1 Muscle Loss Explained |
Description
Pfizer's experience suggests it is a chemotype-dependent problem, not a class problem
Importantly, the review also notes that individual responses to incretin-based therapies can vary substantially, and weight regain commonly occurs if treatment is discontinued, highlighting the chronic nature of obesity management
How to prevent the microvascular complications of type 2 diabetes beyond glucose control
Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy
Overcoming addictions One of the most surprising side effects of these medications has nothing to do with food
Nature 528, 262266
